Aspira Women’s Health (NASDAQ:AWH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a report issued on Wednesday morning.

Separately, Alliance Global Partners decreased their target price on shares of Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

NASDAQ AWH opened at $0.81 on Wednesday. Aspira Women’s Health has a one year low of $0.77 and a one year high of $6.01. The stock has a 50-day moving average of $1.14 and a 200 day moving average of $2.12. The company has a market capitalization of $10.04 million, a price-to-earnings ratio of -0.56 and a beta of 1.48.

Aspira Women’s Health (NASDAQ:AWH) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The company had revenue of $2.42 million during the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the firm earned ($0.28) earnings per share. On average, equities analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Institutional Trading of Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its stake in Aspira Women’s Health Inc. (NASDAQ:AWH) by 43.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 179,371 shares of the company’s stock after buying an additional 53,997 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.73% of Aspira Women’s Health worth $732,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.19% of the company’s stock.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.